Key Highlights

● Adagene Inc. furnished a Form 6-K disclosing that Executive Director of Finance Chunfang (Vicky) Gu will step down effective September 30, 2026, citing personal reasons.

● The filing quotes Gu confirming she has no disagreement with the Board of Directors and no matters requiring the board's or shareholders' attention.

● The Form 6-K was signed by CEO Peter Luo on September 25, 2026 and does not name an interim or permanent successor for Gu's role.

● As a foreign private issuer, Adagene furnishes routine updates on Form 6-K rather than the Form 8-K used by U.S. domestic companies.

Adagene Inc. (NASDAQ:ADAG) furnished a Form 6-K disclosing that Chunfang (Vicky) Gu, its Executive Director of Finance, will step down from her role effective September 30, 2026, citing personal reasons and confirming no disagreement with the company's board.

The Resignation

The filing is brief, consistent with the limited disclosure typically required for a finance-department departure that does not involve the company's principal financial officer or another named executive officer. Gu submitted a formal resignation letter stating her departure is for personal reasons. The filing quotes her confirming she has "no disagreement with the board of directors" and that there are "no matters in relation to her resignation which should be brought to the attention of the Board or the shareholders," language meant to reassure investors that nothing concerning triggered the exit.

Signatory and Process

The Form 6-K was signed by Peter Luo, Adagene's Chief Executive Officer, on September 25, 2026. The filing does not identify who will assume Gu's finance responsibilities on an interim or permanent basis following her September 30 departure date, and it does not name a successor.

Why This Is a 6-K Rather Than an 8-K

Adagene reports to the SEC as a foreign private issuer, which means routine corporate updates like this one are furnished on Form 6-K rather than filed on the Form 8-K used by U.S. domestic companies. Foreign private issuers generally have more flexibility in the timing and content of these disclosures compared to the specific, itemized requirements domestic issuers face under Form 8-K, though the substance disclosed here, a finance executive's resignation, its stated reason, and confirmation of no disagreement with the board, mirrors what a comparable domestic 8-K would typically cover under Item 5.02.

What the Filing Does Not Disclose

The filing does not describe Gu's tenure length at Adagene, her specific responsibilities as Executive Director of Finance, or whether she holds any other titles at the company such as principal accounting officer. It also does not disclose whether the company has begun a search for her replacement, and it provides no detail about Adagene's broader business, pipeline, or financial condition.

Company Background

Adagene Inc. trades on Nasdaq under the ticker ADAG and operates as a biopharmaceutical company; the filing itself does not elaborate on the company's therapeutic focus or clinical-stage programs, limiting its scope strictly to this personnel disclosure.

Succession Details to Follow

Investors should watch for any follow-up 6-K or Annual Report disclosure naming Gu's successor as Executive Director of Finance, and for confirmation of whether her departure affects the company's financial reporting processes or internal controls in the near term, given that Gu will be gone as of September 30, 2026.

The brevity of this filing is itself informative: unlike the detailed severance schedules, compensation tables and biographical disclosures that accompany many executive transitions, Adagene's 6-K here runs only a few paragraphs, confirming an effective date, a stated reason, and the standard no-disagreement language. That brevity is typical for departures below the level of principal financial officer or another Section 16 officer, where the SEC's disclosure requirements are less extensive than for a company's most senior named executives.

Because the filing does not address succession planning, shareholders concerned about continuity in Adagene's finance function will need to watch the company's subsequent filings, including its next annual report on Form 20-F, if applicable to its foreign private issuer status, for any update on how the Executive Director of Finance role will be filled following Gu's exit at the end of September.